The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine

Clinics

Volumn 68, Issue 1, 2013, Pages 19-25

  Liu, Yong ^a   Tan, Ning ^a   Chen, Jiyan ^a   Zhou, Yingling ^a   Chen, Liling ^c   Chen, Shiqun ^b   Chen, Zhujun ^a   Li, Liwen ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b YIBIN UNIVERSITY   (China)

^c Department of Cardiology   (China)

Author keywords

Contrast induced acute kidney injury; Hyperuricemia; Percutaneous coronary intervention; Risk factors

Indexed keywords

CONTRAST MEDIUM; CREATININE;

ACUTE KIDNEY FAILURE; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EPIDEMIOLOGY; FEMALE; HUMAN; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; SEX DIFFERENCE; URINE;

ACUTE KIDNEY INJURY; AGE FACTORS; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTORS; SEX FACTORS;

EID: 84874150018     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(01)OA04     Document Type: Article

References (40)

1. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;69(100):S11e5.
2. Morcos SK. Prevention of contrast media nephrotoxicity following angiographic procedures. J Vasc Interv Radiol. 2005;16(1):13-23, http://dx.doi.org/10.1097/01.RVI.0000145224.02920.C2.
3. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast-associated nephropathy. Arch Intern Med. 2002;162(3):329-36, http://dx.doi.org/10.1001/archinte.162.3.329.
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-64, http://dx.doi.org/10.1161/01.CIR.0000016043.87291.33.
5. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with preexistent chronic renal insufficiency. J Am Coll Cardiol. 2000;36(5):1542-8, http://dx.doi.org/10.1016/S0735-1097(00)00917-7.
6. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003;15(1):18-22.
7. Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50(7):584-90, http://dx. doi.org/10.1016/j.jacc.2007.03.058.
8. Mehran R, Aymong ED, Nikolsky E. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-9.
9. Postlethwaite AE, Kelley WN. Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Intern Med. 1971;74(6):845-52.
10. Mudge GH. Uricosuric action of cholecystographic agents: possible nephrotoxicity. N Engl J Med. 1971;284(17):929-33.
11. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005;25(1):43-9, http://dx.doi.org/10.1016/j.semnephrol.2004. 10.001.
12. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med. 2002;69(8):594,597, 600-2 passim, http://dx.doi.org/10.3949/ccjm.69.8.594.
13. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, et al. Uric acid and the state of the intrarenal reninangiotensin system in humans. Kidney Int. 2004;66(4):1465-70, http://dx. doi.org/10.1111/j.1523-1755.2004.00909.x.
14. Toprak O, Cirit M, Esi E, Postaci N, Yesil M, Bayata S. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv. 2006;67(2):227-35, http://dx. doi.org/10.1002/ccd.20598.
15. Chiou WK, Wang MH, Huang DH, Chiu HT, Lee YJ, Lin JD. The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. J Epidemiol. 2010;20(3):219-24.
16. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57(6):845-52, http://dx.doi.org/10.1016/j.metabol.2008.01.030.
17. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9):1780-5, http://dx.doi.org/10.1016/j.jacc.2004.07.043.
18. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. Am J Roentgenol. 2004;183(6):1673-89.
19. Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S. Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int. 1991;40(4):632-42, http://dx.doi.org/10.1038/ki.1991.255.
20. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57(19):1920-59, http://dx.doi.org/10.1016/j.jacc.2011.02.009.
21. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Kolh P, Wijns W, Danchin N, Di Mario C, et al. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2010;38 Suppl:S1-S52, http://dx.doi.org/10.1016/j.ejcts.2010.08.019.
22. Chong E, Poh KK, Liang S, Tan HC. Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine. Ann Acad Med Singapore. 2010;39:374-80.
23. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239-47.
24. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest. 2001;31(4):318-21, http://dx.doi.org/10.1046/j.1365-2362.2001. 00812.x.
25. Postlethwaite AE, Kelley WN. Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Intern Med. 1971;74(6):845-52.
26. Mudge GH. Uricosuric action of cholecystographic agents: possible nephrotoxicity. N Engl J Med. 1971;284(17):929-33.
27. Dudzinski PJ, Petrone AF, Persoff M, Callaghan EE. Acute renal failure following high dose excretory urography in dehydrated patients. J Urol.1971;106(5):619-21.
28. Park SH, Shin WY, Lee EY, Gil HW, Lee SW, Lee SJ, Jin DK, Hong SY. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J. 2011;75(3):692-7, http://dx.doi.org/10.1253/circj.CJ-10-0631.
29. Tapia E, Sanchez-Lozada LG, Sanchez-Gonzalez DJ, Medina-Campos ON, Soto V, Avila-Casado C, et al. Amelioration of inflammation and oxidative stress preserves microvascular structure, and decrease systemic and glomerular pressure, and proteinuria in albumin overload (OA) rats. J Am Soc Nephrol 2006;17:685A.
30. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739-42, http://dx.doi.org/10.1111/j.1523-1755.2005.00273.x.
31. Kang D-H, Park SK, Lee IK, Johnson RJ. Uric acid induced C-reactive protein (CRP) expression: Implication on cell proliferation and nitric oxide production in human vascular cells. J Am Soc Nephrol. 2005;16(12):3553-62, http://dx.doi.org/10.1681/ASN.2005050572.
32. Kanellis J, Watanabe S, Li JH, Kang D-H, Li P, Nakagawa T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287-93, http://dx.doi.org/10.1161/01.HYP.0000072820.07472.3B.
33. Kang DH, Kim JH, Shin KS, Kim SJ, Johnson RJ. Uric acid induced apoptosis of HUVEC via ROS-dependent path-way, but not of HVSMC [Abstract]. J Am Soc Nephrol.2005;16:167A, http://dx.doi.org/10.1681/ASN.2005050572.
34. Pakfetrat M, NikooMH, Malekmakan L, TabandeM, Roozbeh J, Reisjalali G, et al. Risk Factors for Contrast-related Acute Kidney Injury According to Risk, Injury, Failure, Loss, and End-stage Criteria in Patients with Coronary Interventions. Iran J Kidney Dis. 2010;4(2):116-22.
35. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2): 225-32, http://dx.doi.org/10.1002/art.24164.
36. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796-803.
37. Kowalczyk J, Francuz P, Swoboda R, Lenarczyk R, Sredniawa B, Golda A, et al. Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention. Nephron Clin Pract. 2010;116(2):c114-22, http://dx.doi.org/10.1159/000314660.
38. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Müller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, Landmesser U: Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 2004;110(15):2175-9, http://dx.doi.org/10.1161/01.CIR.0000144303.24894.1C.
39. Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SR. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci. 2003;105(4):425-30, http://dx.doi.org/10.1042/CS20030149.
40. Erol T, Tekin A, Katircibasi MT, Sezgin N, Bilgi M, Tekin G, et al. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol. 2012 May 8. [Epub ahead of print].